User login
Key clinical point: Adjuvant chemotherapy significantly improved the overall survival (OS) outcomes in patients with small-size (T1b and T1c) node-negative triple-negative breast cancer (TNBC).
Major finding: Adjuvant chemotherapy led to significantly better OS outcomes in patients with T1b TNBC (adjusted hazard ratio [aHR] 0.52; P < .001) and improved both OS (aHR 0.54; P < .001) and breast cancer-specific survival (aHR 0.79; P = .043) in those with T1c TNBC.
Study details: This retrospective study analyzed the data from the Surveillance, Epidemiology, and End Results (SEER) database and included 11,510 women with T1b (n = 3388) or T1c (n = 8122) node-negative TNBC, of whom 8029 patients received adjuvant chemotherapy.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Carbajal-Ochoa W et al. Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer. Breast Cancer Res Treat. 2023 (Oct 13). doi: 10.1007/s10549-023-07132-6
Key clinical point: Adjuvant chemotherapy significantly improved the overall survival (OS) outcomes in patients with small-size (T1b and T1c) node-negative triple-negative breast cancer (TNBC).
Major finding: Adjuvant chemotherapy led to significantly better OS outcomes in patients with T1b TNBC (adjusted hazard ratio [aHR] 0.52; P < .001) and improved both OS (aHR 0.54; P < .001) and breast cancer-specific survival (aHR 0.79; P = .043) in those with T1c TNBC.
Study details: This retrospective study analyzed the data from the Surveillance, Epidemiology, and End Results (SEER) database and included 11,510 women with T1b (n = 3388) or T1c (n = 8122) node-negative TNBC, of whom 8029 patients received adjuvant chemotherapy.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Carbajal-Ochoa W et al. Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer. Breast Cancer Res Treat. 2023 (Oct 13). doi: 10.1007/s10549-023-07132-6
Key clinical point: Adjuvant chemotherapy significantly improved the overall survival (OS) outcomes in patients with small-size (T1b and T1c) node-negative triple-negative breast cancer (TNBC).
Major finding: Adjuvant chemotherapy led to significantly better OS outcomes in patients with T1b TNBC (adjusted hazard ratio [aHR] 0.52; P < .001) and improved both OS (aHR 0.54; P < .001) and breast cancer-specific survival (aHR 0.79; P = .043) in those with T1c TNBC.
Study details: This retrospective study analyzed the data from the Surveillance, Epidemiology, and End Results (SEER) database and included 11,510 women with T1b (n = 3388) or T1c (n = 8122) node-negative TNBC, of whom 8029 patients received adjuvant chemotherapy.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Carbajal-Ochoa W et al. Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer. Breast Cancer Res Treat. 2023 (Oct 13). doi: 10.1007/s10549-023-07132-6